Published in Am J Hum Genet on September 27, 2005
Lrp5 functions in bone to regulate bone mass. Nat Med (2011) 5.33
WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med (2013) 4.52
Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell (2009) 2.63
Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol (2011) 2.12
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas (2010) 1.51
Wnt signaling in bone metabolism. J Bone Miner Metab (2009) 1.48
Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet (2013) 1.39
The Norrin/Frizzled4 signaling pathway in retinal vascular development and disease. Trends Mol Med (2010) 1.38
Diseases of Wnt signaling. Rev Endocr Metab Disord (2006) 1.36
Unexplained fractures in infancy: looking for fragile bones. Arch Dis Child (2007) 1.22
An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling. PLoS Med (2007) 1.03
Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate of human mesenchymal (stromal) stem cells through canonical Wnt signaling and C/EBP. J Biol Chem (2010) 1.02
Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet (2012) 1.00
Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur J Hum Genet (2011) 0.97
Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone (2008) 0.95
Familial exudative vitreoretinopathy and related retinopathies. Eye (Lond) (2014) 0.95
Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed) (2014) 0.94
A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice. Bone Res (2013) 0.94
Reduced bone mineral density and hyaloid vasculature remnants in a consanguineous recessive FEVR family with a mutation in LRP5. Br J Ophthalmol (2006) 0.91
Mechanotransduction in bone tissue: The A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner. Bone (2012) 0.91
Identification of FZD4 and LRP5 mutations in 11 of 49 families with familial exudative vitreoretinopathy. Mol Vis (2012) 0.91
Moderate reduction of Norrin signaling activity associated with the causative missense mutations identified in patients with familial exudative vitreoretinopathy. Hum Genet (2007) 0.86
LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion. Cell Metab (2015) 0.86
A specific role for phosphoinositide 3-kinase and AKT in osteoblasts? Front Endocrinol (Lausanne) (2012) 0.86
Next generation sequencing identifies mutations in Atonal homolog 7 (ATOH7) in families with global eye developmental defects. Hum Mol Genet (2011) 0.84
Identification of two novel LRP5 mutations in families with familial exudative vitreoretinopathy. Mol Vis (2014) 0.83
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health (2015) 0.83
Effects of glucocorticoid treatment on bone strength. J Bone Miner Metab (2010) 0.82
Identification of the first deletion in the LRP5 gene in a patient with autosomal dominant osteopetrosis type I. Bone (2011) 0.82
The role of the hypoxia response in shaping retinal vascular development in the absence of Norrin/Frizzled4 signaling. Invest Ophthalmol Vis Sci (2014) 0.81
High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo. J Bone Miner Res (2015) 0.79
The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment. Ital J Pediatr (2014) 0.77
Fractures on bisphosphonates in osteoporosis pseudoglioma syndrome (OPPG): pQCT shows poor bone density and structure. Bone (2015) 0.76
Intrinsic disorder in spondins and some of their interacting partners. Intrinsically Disord Proteins (2016) 0.75
Rare causes of osteoporosis. Clin Cases Miner Bone Metab (2015) 0.75
Osteoporosis-Pseudoglioma in a Mauritanian Child due to a Novel Mutation in LRP5. Case Rep Genet (2016) 0.75
The Genetic Causes of Nonsyndromic Congenital Retinal Detachment: A Genetic and Phenotypic Study of Pakistani Families. Invest Ophthalmol Vis Sci (2017) 0.75
Extracellular LDLR repeats modulate Wnt signaling activity by promoting LRP6 receptor endocytosis mediated by the Itch E3 ubiquitin ligase. Genes Cancer (2017) 0.75
Potential blindness in children of patients with hereditary bone disease. Osteoporos Int (2015) 0.75
Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG). Osteoporos Int (2017) 0.75
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
LDL-receptor-related proteins in Wnt signal transduction. Nature (2000) 6.94
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
An LDL-receptor-related protein mediates Wnt signalling in mice. Nature (2000) 6.34
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol (2002) 6.20
Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science (2001) 5.22
Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell (2004) 5.04
Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science (1994) 4.86
Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A (2005) 4.48
High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res (2003) 3.48
Segregation at three loci explains familial and population risk in Hirschsprung disease. Nat Genet (2002) 3.07
Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A (2002) 2.93
Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet (2002) 2.90
Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet (2003) 2.86
Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet (2004) 2.70
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res (2004) 2.46
A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy. Nat Genet (1993) 2.23
Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol (2005) 2.00
Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell (2003) 1.99
Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet (2004) 1.97
Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet (1996) 1.89
Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. Am J Hum Genet (2004) 1.66
Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem (2002) 1.53
Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. Hum Mutat (2005) 1.51
LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density. J Hum Genet (2004) 1.47
DNA polymerase active site is highly mutable: evolutionary consequences. Proc Natl Acad Sci U S A (2000) 1.41
Retinal vasculature changes in Norrie disease mice. Invest Ophthalmol Vis Sci (1998) 1.33
The ocular form of osteogenesis imperfecta: a new autosomal recessive syndrome. Clin Genet (1985) 1.27
Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res (2005) 1.27
LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. Bone (2005) 1.11
Osteoporosis-pseudoglioma syndrome: report of three affected sibs and an overview. Am J Med Genet (1985) 1.08
Osteoporosis-pseudoglioma or osteogenesis imperfecta? Clin Genet (1986) 1.04
Osteoporosis-pseudoglioma syndrome. Am J Med Genet (1993) 1.00
Osteoporosis-pseudoglioma syndrome: clinical, morphological, and biochemical studies. J Med Genet (1988) 0.98
Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr (2000) 0.95
Decreased bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome. Isr Med Assoc J (2003) 0.90
The osteoporosis pseudoglioma syndrome. Update and report on two affected siblings. Pediatr Radiol (1988) 0.86
Persistent hyperplastic primary vitreous in a family with osteoporosis-pseudoglioma syndrome. Clin Dysmorphol (1997) 0.81
Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. Genome Res (2009) 2.31
CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression. PLoS Genet (2010) 2.20
Epigenomic enhancer profiling defines a signature of colon cancer. Science (2012) 2.15
Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. Nat Methods (2008) 2.02
Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab (2005) 1.87
Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther (2002) 1.48
Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet (2009) 1.47
Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics (2003) 1.28
The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals. Am J Med Genet C Semin Med Genet (2012) 1.23
The mutational spectrum of brachydactyly type C. Am J Med Genet (2002) 1.22
Consequences of disease-causing mutations on lubricin protein synthesis, secretion, and post-translational processing. J Biol Chem (2005) 1.08
Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet (2012) 1.00
A mutation in the signal sequence of LRP5 in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats. Hum Mutat (2009) 0.92
Reaction kinetics of biotinylated organophosphorus toxicant, FP-biotin, with human acetylcholinesterase and human butyrylcholinesterase. Chem Res Toxicol (2005) 0.90
H3K4me3 inversely correlates with DNA methylation at a large class of non-CpG-island-containing start sites. Genome Med (2012) 0.90
High activity of human butyrylcholinesterase at low pH in the presence of excess butyrylthiocholine. Eur J Biochem (2003) 0.85
Temporal and spatial expression of CCN genes in zebrafish. Dev Dyn (2010) 0.84
Otitis media in a new mouse model for CHARGE syndrome with a deletion in the Chd7 gene. PLoS One (2012) 0.83
Substrate activation in acetylcholinesterase induced by low pH or mutation in the pi-cation subsite. Biochim Biophys Acta (2002) 0.82
Protective effects of C-type natriuretic peptide on linear growth and articular cartilage integrity in a mouse model of inflammatory arthritis. Arthritis Rheumatol (2014) 0.78
Mixed clefting type in Rapp-Hodgkin syndrome. Am J Med Genet (2002) 0.78
A Naturally Occurring Genetic Variant in the Human Chorionic Gonadotropin-β Gene 5 Is Assembly Inefficient. Endocrinology (1999) 0.75